Explosomes: A new modality for DEB-TACE local delivery of sorafenib: In vivo proof of sustained release
Authors:
- 23 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 364, 12-22
Abstract
No abstract availableKeywords
Funding Information
- Université de Genève
- Gutenberg Forschungskolleg
This publication has 44 references indexed in Scilit:
- Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaCancer, 2012
- HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 2011
- Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trialsAnti-Cancer Drugs, 2010
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practiceJournal of Pharmaceutical and Biomedical Analysis, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2008
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- Solid supported lipid bilayers: From biophysical studies to sensor designSurface Science Reports, 2006
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002